You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of Fludase for Prevention of Influenza
SBC: Nexbio, Inc. Topic: N/ADESCRIPTION (provided by applicant): Influenza is characterized by recurrent annual epidemics and periodic major worldwide pandemics. Because of the high disease-related morbidity and mortality, direct and indirect socio-economic impacts of influenza are enormous. In the last 100 years, there have been 3 major influenza pandemics. It has been about thirty years since the last pandemic. A new pand ...
SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
Virtual Bone Biopsy: Transfer to the clinical arena
SBC: MICROMRI, INC. Topic: N/AOsteoporosis is a major community health problem for which several effective FDA approved therapies exist, but which remains largely undiagnosed and untreated. While bone densitometry using dual-energy x-ray absorptiometry (DXA) is the current "gold standard" in osteoporosis diagnosis, controlled clinical trials have highlighted its sensitivity and specificity limitations at the individual patient ...
SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
CMV Immunotherapeutic Vaccine
SBC: VICAL, INC. Topic: N/ADESCRIPTION (provided by applicant): Vical Inc. of San Diego, Ca. is the largest GMP manufacturer of plasmid DNA for vaccine clinical trials in the world. We have manufactured GMP plasmid DNA vaccines that are being used or entering clinical trials for HIV (in the US and China), malaria (up to 9 plasmids), Ebola, WNV, and SARS. Vical has undertaken an internal Product Development Program that focu ...
SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
Genome-Wide Scan for Alzheimer's Associated Genes
SBC: Perlegen Sciences, Inc. Topic: N/ADESCRIPTION (provided by applicant): The goal of this study is to identify the genetic determinants of late-onset Alzheimer's disease (AD). The proposed study uses Perlegen Sciences' high-density oligonucleotide array-based genotyping platform to genotype over 1.5 million single nucleotide polymorphisms (SNPs) across the genome in the context of a whole-genome association study of late-onset AD. ...
SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
Low Antigenicity Factor VIII
SBC: Octagen Corporation Topic: N/ADESCRIPTION (provided by applicant): Octagen's broad, long-term objective is to complete the clinical development and secure FDA approval of its b-domain deleted recombinant factor VIII (OBI-1), a low antigenicity version of factor VIM (fVIII). OBI-1 is designed for the treatment of patients with inhibitory, neutralizing antibodies to human fVIII. Such "inhibitor" patients include congenital hemop ...
SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
Inhibition of hepatitis C by RNA-based therapeutics
SBC: Somagenics, Inc. Topic: N/ADESCRIPTION (provided by applicant): Treatment and prevention of hepatitis C virus (HCV) infections remains a major challenge for controlling this worldwide health problem; existing therapies are only partially effective and no vaccine is currently available. RNA interference offers the potential of a novel therapeutic approach for treating HCV infections. Toward this end, we are developing small ...
SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
Riluzole Prodrugs for Melanoma and ALS
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: 102We have discovered a novel Type IIb prodrug of riluzole, trigriluzole (FC-4157, BVH-4157), which has the potential to substantially improve therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action. While riluzole has shown promising efficacy in treating melanoma in patients, trigrilluzole is andgt;20X more potent than riluzo ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a urine test for the early detection of liver cancer
SBC: JBS SCIENCE INC Topic: 102Development of a urine test for the early detection of liver cancer The need to develop an effective method for detecting liver cancer is urgent. HCC, a primary liver cancer, is the third leading cause of cancer deaths worldwide and the fastest rising cancer in US. HCC has a 5-year survival rate of less than 15%, if detected early, the survival rate can be as high as 40%. The survival rate drops s ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
SBC: VENATORX PHARMACEUTICALS INC Topic: NIAIDProject Summary This 3-year Phase II SBIR Application focuses on advancing the lead “ultra-broad-spectrum” carbapenem (USBC) VNRX-4099, possessing an unprecedented antibacterial spectrum of activity including MRSA, Enterobacteriaceae and Pseudomonas aeruginosa, to IND filing status. The UBSC VNRX-4099 will be paired with a proprietary in-house β-lactamase inhibitor VNRX-5133 (BLI) to protect ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II
SBC: CHROMOLOGIC LLC Topic: NIAIDAbstract In response to PA-15-065, the broad long-term goal of this project is to develop a portable radiation biodosimeter to be used at the point-of-care (POC) for assessing precise radiation exposure and susceptibility for acute radiation syndrome (ARS) within the first 7 days of exposure starting with ~250 µL of blood collected from a finger stick and a turnaround time (TAT) of less than 40 m ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health